Journal: J. Med. Chem. / Year: 2018 Title: Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: ...Title: Discovery of 7-Oxo-2,4,5,7-tetrahydro-6 H-pyrazolo[3,4- c]pyridine Derivatives as Potent, Orally Available, and Brain-Penetrating Receptor Interacting Protein 1 (RIP1) Kinase Inhibitors: Analysis of Structure-Kinetic Relationships. Authors: Yoshikawa, M. / Saitoh, M. / Katoh, T. / Seki, T. / Bigi, S.V. / Shimizu, Y. / Ishii, T. / Okai, T. / Kuno, M. / Hattori, H. / Watanabe, E. / Saikatendu, K.S. / Zou, H. / Nakakariya, M. / ...Authors: Yoshikawa, M. / Saitoh, M. / Katoh, T. / Seki, T. / Bigi, S.V. / Shimizu, Y. / Ishii, T. / Okai, T. / Kuno, M. / Hattori, H. / Watanabe, E. / Saikatendu, K.S. / Zou, H. / Nakakariya, M. / Tatamiya, T. / Nakada, Y. / Yogo, T.
Protocol: SINGLE WAVELENGTH / Monochromatic (M) / Laue (L): M / Scattering type: x-ray
Radiation wavelength
Wavelength: 0.97 Å / Relative weight: 1
Reflection
Resolution: 2.52→95.39 Å / Num. obs: 37759 / % possible obs: 99 % / Redundancy: 3.6 % / Net I/σ(I): 12.9
Reflection shell
Resolution: 2.52→2.58 Å
-
Processing
Software
Name
Version
Classification
REFMAC
5.8.0049
refinement
HKL-2000
datareduction
HKL-2000
datascaling
MOLREP
phasing
Refinement
Resolution: 2.52→95.39 Å / Cor.coef. Fo:Fc: 0.929 / Cor.coef. Fo:Fc free: 0.882 / SU B: 45.254 / SU ML: 0.419 / Cross valid method: THROUGHOUT / ESU R Free: 0.38 / Details: HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS
Rfactor
Num. reflection
% reflection
Selection details
Rfree
0.29643
1976
5 %
RANDOM
Rwork
0.23625
-
-
-
obs
0.24554
37639
98.95 %
-
Solvent computation
Ion probe radii: 0.8 Å / Shrinkage radii: 0.8 Å / VDW probe radii: 1.2 Å